

ABSTRACT

MS
C2
5
1

The present invention relates to the ligand polypeptide has prolactin secretion modulating activity, and has a function of modulating placental function.

In this regard, the ligand polypeptide can be used as a prolactin secretion-stimulating agent for the prevention and treatment of certain diseases associated with prolactin secretion, such as hypoovarianism, 10 gonocyst cacogenesis, menopausal syndrome, euthyroid hypometabolism. In addition, the ligand polypeptide of the invention can be used with advantage as a aphrodisiac.

On the other hand, the ligand polypeptide of the 15 invention can be used with advantage as a prolactin secretion inhibitory agent in the prevention and treatment of certain diseases associated with prolactin secretion, such as pituitary adenomatosis, brain tumor, emmeniopathy, autoimmune disease, prolactinoma, 20 infertility, impotence, amenorrhea, galactorrhea, acromegaly, Chiari-Frommel syndrome, Argonz-del Castillo syndrome, Forbes-Albright syndrome, lymphoma, Sheehan syndrome or dyszoospermia.

In addition, the ligand polypeptide of the 25 present invention is used as an agent for treating or preventing chriocarcinomia, hydatid mole, irruption mole, abortion, unthrifty fetus, abnormal saccharometabolism, abnormal lipidmetabolism or oxytocia.